WEBULL
WebtradeDownload

How Investors May Respond To Humana (HUM) Expanded Medicare Advantage Plans

Simply Wall St · 2d ago
  • In October 2026, Humana announced its 2027 Medicare Advantage lineup, featuring $0 in-network primary care and lab services, dental, vision and hearing benefits, and $0 or low premiums across plans offered in roughly 2,600 counties, covering more than 80% of U.S. counties.
  • The expansion of Chronic Condition Special Needs Plans into Pennsylvania, Utah and Wisconsin gives Humana a broader platform for coordinated care aimed at people with qualifying long term conditions.
  • We will now look at how Humana's broader 2027 Medicare Advantage footprint could reshape the investment narrative for the insurer.

Scan how Humana’s Medicare Advantage push compares with other insurers by reviewing hand picked list of solid balance sheet and fundamentals (25 results) for potential exposure to similar health coverage themes.

Humana Investment Narrative Recap

To own Humana, you need to believe its Medicare Advantage margin restoration plan can coexist with product designs that remain attractive to seniors. The 2027 lineup points to a push for broader membership reach with $0 or low premiums and richer everyday benefits. The near term swing factor still looks like execution on medical cost control and operating efficiency, not headline benefit features.

The biggest risk stays intact. Humana is pruning about 600,000 lower return Medicare Advantage members while operating under tight regulatory and coding scrutiny and lower current net margins of 0.9%. If migration into higher value plans disappoints, or oversight drives higher compliance costs, that would work directly against the margin recovery narrative.

The most relevant development for that story is the 2027 Medicare Advantage expansion to roughly 2,600 counties with standardized core benefits. This gives Humana a wider stage to test whether its value based and CenterWell centric model can support both member retention and cost discipline. It also interacts directly with the multiyear plan to target at least a 3% pretax margin by 2028.

Expanded Chronic Condition Special Needs Plans in Pennsylvania, Utah and Wisconsin slot neatly into the same thesis. These products lean on coordinated care and Medicare Advantage rules, which ties them closely to regulatory and coding risk, Stars outcomes and quality bonuses. For you as an investor, execution on these specialized plans is an operational catalyst and a real time stress test of the whole Medicare Advantage strategy.

How Humana's Medicare Advantage Expansion Connects To The Numbers

Humana's narrative projects US$187.3b revenue and US$3.4b earnings by 2029. This is based on analysts' assumption of 8.7% yearly revenue growth and implies about a 2.6x earnings increase from US$1.3b today.

Uncover why Humana's fair value indicates an 8% potential upside to its current price that could narrow quickly.

NYSE:HUM 1-Year Stock Price Chart
NYSE:HUM 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view around Humana focuses less on benefit design and more on policy risk. The most bearish analysts, who were modeling about US$172.3b of revenue and US$2.6b in earnings by 2029 before this news, see heavier Medicare Advantage regulation as the swing factor. Use that gap to explore how your own expectations might shift after the 2027 rollout.

Explore 5 other Humana fair value estimates, including one that suggests as much as 45% downside from the current price!

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Humana?

Once you have a view on Humana, it can help to widen the lens and compare it with other businesses that fit different risk and income profiles using the Simply Wall St Screener.

  • If you want potential high growth but accept higher volatility, scan a focused group of 8 elite penny stocks with strong financials that already show stronger balance sheets than many peers.
  • For investors who care most about paying a fair price for quality, filter the market through 31 high quality undervalued stocks that pair solid financials with compressed valuations.
  • If income is your main priority, narrow your search to 7 dividend fortresses that combine higher yields with an emphasis on resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.